Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
-
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
-
Fractyl Health to Participate in Upcoming September Investor Conferences
-
Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single
-
Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024
-
Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs
-
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
-
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
-
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Platform at ADA 2024.